Immune checkpoint inhibitors in advanced non–small cell lung cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major changes to the therapeutic landscape of lung cancer. Improvements in overall survival relative to standard chemotherapy have been observed in the first‐line and second‐line therapy settings for patients with advanced non–small cell lung cancer (NSCLC) who are treated with immune checkpoint inhibitors. Consequently, every patient with advanced‐stage NSCLC is now a candidate for immune checkpoint inhibitor therapy. However, it is clear that the benefit from therapy is not universal, and identification of biomarkers to select therapy has assumed importance. In addition to programmed cell death receptor ligand 1 expression, both tissue‐based and blood‐based markers are under evaluation to select patients. In an era of increasing costs of care and potential for toxicities related to immune checkpoint inhibition, proper patient selection is critical to the optimal use of this new class of agents. In addition, development of novel combination approaches has also emerged as an important way to improve the efficacy of immune checkpoint inhibition. Studies in earlier stages of NSCLC are already underway with the hope of improving the cure rate. In this article, the authors review the current landscape of immune checkpoint inhibitors in the treatment of advanced NSCLC. Cancer 2018;124:248‐61. © 2017 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 2×
“6 months in the docetaxel arm, suggesting that objective responses were more durable with immune checkpoint inhibition.(66) Another important observation in that study was related to the higher efficacy results in patients who had tumors that expressed higher levels of PD-L1, as assessed by immunohistochemistry.”
ResultNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“The observations from CheckMate 063 were confirmed by a phase 3 study that compared nivolumab versus docetaxel in patients with advanced-stage squamous cell cancer of the lung (CheckMate 017).(65) In total, 272 patients were randomized to receive either nivolumab 3 mg/kg every 2 weeks or docetaxel 75 mg/m(2) every 3 w…”
MethodResultOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“CHECKPOINT INHIBITORS The tumor environment is characterized by a state of immune tolerance maintained by various mechanisms, which include the recruitment of regulatory immune cells, the release of immunosuppressive molecules, and the expression of inhibitory receptors on tumor-infiltrating T cells that dampen immune…”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 3×
“5% of adverse events were grade 3 or higher.(60) Similar results were observed with durvalumab and avelumab (inhibitors of PD-L1) in patients with advanced NSCLC,(61) and the overall response rates for the 2 agents were 14% and 12%, respec-”
BackgroundResultInfluentialPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 14×
“The Bristol-Myers Squibb (BMS)-026 study compared nivolumab versus chemotherapy in advanced NSCLC.”
BackgroundInfluential
Cited by
Tsao, M. S., Kerr, K. M., Kockx, M., Beasley, M.-B., Borczuk, A. C., Botling, J., Bubendorf, L., Chirieac, L., Chen, G., Chou, T.-Y., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.013 · Cited by 794
Borghaei, H., Gettinger, S., Vokes, E. E., Chow, L. Q. M., Burgio, M. A., de Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O. A., Chiari, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01605 · Cited by 656
Suresh, K., Voong, K. R., Shankar, B., Forde, P. M., Ettinger, D. S., Marrone, K. A., Kelly, R. J., Hann, C. L., Levy, B., Feliciano, J. L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2035 · Cited by 434
Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1390 · Cited by 408
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
Suresh, K., Naidoo, J., Lin, C. T., & Danoff, S. (2018) · Chest · doi:10.1016/j.chest.2018.08.1048 · Cited by 379
Scafoglio, C. R., Villegas, B., Abdelhady, G., Bailey, S. T., Liu, J., Shirali, A. S., Wallace, W. D., Magyar, C. E., Grogan, T. R., Elashoff, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat5933 · Cited by 176
“Despite the success of targeted and immune-based therapies in NSCLC (1, 2), early diagnosis and surgical resection of early-stage disease remain the best opportunity for a cure: The 5-year survival of patients with NSCLC is 55.”
BackgroundInfluentialJia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32191 · Cited by 164
Hwang, M., Canzoniero, J. V., Rosner, S., Zhang, G., White, J. R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004688 · Cited by 150
Zhang, N., Jiang, J., Tang, S., & Sun, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106677 · Cited by 109
Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC
Yang, Y., Ye, M., Song, Y., Xing, W., Zhao, X., Li, Y., Shen, J., Zhou, J., Arikawa, K., Wu, S., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00785-9 · Cited by 36
Biological Basis for Novel Mesothelioma Therapies
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01462-2 · Cited by 31
Metadata
- Authors
- Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2017-12-06
- Volume
- 124
- Issue
- 2
- Pages
- 248-261
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2774557779
- Cited by
- 121
- References
- 44
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.